Current:Home > InvestEU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company Grail -Pinnacle Profit Strategies
EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company Grail
View
Date:2025-04-15 22:51:21
BRUSSELS (AP) — The European Union on Thursday ordered U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators in the 27-nation bloc.
The EU already slapped a $475 million fine on Illumina over the summer for jumping the gun on the acquisition without its consent. Now, the order to unwind the deal “restores competition in the development of early cancer detection tests,” EU antitrust Commissioner Didier Reynders said.
“By ordering Illumina to restore Grail’s independence, we ensure a level playing field in this crucial market to the ultimate benefit of European consumers,” he said.
Illumina said it is reviewing the order to sell Grail. The company also has previously asked the EU’s highest court to rule on its challenge to the bloc’s ability to review the merger.
Allowing the deal to stand would have undermined the credibility of EU regulators. Companies almost invariably play by the rules and wait to complete an acquisition or merger until antitrust authorities have cleared it, according to the European Commission, the EU’s executive arm and top antitrust enforcer.
Illumina announced the acquisition of Grail in 2020, but the commission said the company broke EU merger rules by completing the deal without its consent. The commission prohibited the deal in September 2022.
The EU accused Illumina and Grail of knowingly and deliberately merging before getting clearance in what amounted to a vital infringement of the rules.
Illumina must “restore the situation prevailing before” the acquisition, regulators said, and how Illumina divests itself of Grail also needs EU approval.
Regulators worldwide have targeted the deal. The Federal Trade Commission ordered Illumina to sell Grail earlier this year after finding the merger would “stifle competition and innovation in the U.S. market for life-saving cancer tests.”
The EU said the acquisition would squeeze out competitors and give Illumina too dominant of a position in the market.
San Diego-based Illumina is a major supplier of next-generation sequencing systems for genetic and genomic analysis, while Grail is a health company developing blood tests to try to catch cancer early.
veryGood! (11)
Related
- Why we love Bear Pond Books, a ski town bookstore with a French bulldog 'Staff Pup'
- 'He just punched me': Video shows combative arrest of Philadelphia LGBTQ official, husband
- The Daily Money: File your taxes for free
- California man is first in the US to be charged with smuggling greenhouse gases, prosecutors say
- Israel lets Palestinians go back to northern Gaza for first time in over a year as cease
- Crew Dragon docks with space station, bringing four fresh crew members to the outpost
- Conspiracies hinder GOP’s efforts in Kansas to cut the time for returning mail ballots
- New lawsuit blames Texas' Smokehouse Creek fire on power company
- Which apps offer encrypted messaging? How to switch and what to know after feds’ warning
- Dartmouth men's basketball team votes to unionize, shaking up college sports
Ranking
- Tree trimmer dead after getting caught in wood chipper at Florida town hall
- 5 die in fiery small plane crash off Nashville interstate
- Conspiracies hinder GOP’s efforts in Kansas to cut the time for returning mail ballots
- California man is first in the US to be charged with smuggling greenhouse gases, prosecutors say
- Off the Grid: Sally breaks down USA TODAY's daily crossword puzzle, Triathlon
- New Broadway musical Suffs shines a spotlight on the women's suffrage movement
- Pregnant Ayesha Curry Shares the Lessons She’s Passing on to Her 4 Kids
- EAGLEEYE COIN: The Rise of Decentralized Finance (DeFi)
Recommendation
Don't let hackers fool you with a 'scam
Apple fined almost $2 billion by EU for giving its music streaming service leg up over rivals'
Houston still No. 1, while Marquette and Kansas tumble in USA TODAY Sports men's basketball poll
Multiple explosions, fire projecting debris into the air at industrial location in Detroit suburb
SFO's new sensory room helps neurodivergent travelers fight flying jitters
Toyota, Jeep, Hyundai and Ford among 1.4 million vehicles recalled: Check car recalls here
Former Twitter executives sue Elon Musk over firings, seek more than $128 million in severance
'The Harlem Renaissance' and what is Black art for?